Investment
Features
FeesSafety
Academy
More
Pluang+

NEOS Russell 2000 High-Income ETF rated BUY with 8%-12% return target and 13% yield.

Analyst Insights
14 Aug 2026
Seeking Alpha
View Source
Bullish
NEOS Russell 2000 High-Income ETF rated BUY with 8%-12% return target and 13% yield.

The NEOS Russell 2000 High-Income ETF (IWMI) is rated a BUY, targeting an 8% to 12% total return over the next 6 to 12 months. Its attractive 13% trailing yield offers strong income while maintaining exposure to Russell 2000 upside with lower volatility compared to peers. The fund uses a flexible option strategy to generate income without sacrificing total returns, especially in volatile or sideways small-cap markets. Its diversified sector mix in healthcare, financials, and industrials positions it well if small-cap leadership expands beyond technology, enhancing portfolio diversification.

More News

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...

Market News
Bullish
50 minutes ago
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...

Market News
Bullish
1 hour ago
Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...

Company Fundamentals
Bullish
2 hours ago
Papertrade tightens trading limits after alleging price manipulation on Hyperliquid for synthetic BTC and ETH contracts

Papertrade tightens trading limits after alleging price manipulation on Hyperliquid for synthetic BTC and ETH contracts

Papertrade has tightened limits on new trading exposure for its synthetic Bitcoin and Ether contracts after alleging that prices on Hyperliquid, used as a reference, were targeted for manipulation. The platform initially allowed up to $1 billion in o...

Market News
Bearish
4 hours ago
Lightning Development Kit patches Bitcoin vulnerability that risked fund theft via channel state conflicts

Lightning Development Kit patches Bitcoin vulnerability that risked fund theft via channel state conflicts

The Lightning Development Kit (LDK) released updates 0.2.7 and 0.1.13 to fix a vulnerability that allowed malicious peers to create conflicting channel states, potentially stealing Bitcoin from affected Lightning apps. The flaw enabled a peer to fals...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App